NanoHive Medical, LLC, a highly innovative spinal orthopedics company, is pleased to announce the closing of a venture debt round to support continued adoption of its proprietary Soft Titanium® interbody fusion devices. The debt was provided by Kenston Capital Partners, LLC and its affiliates with Outcome Capital, LLC acting as strategic and financial advisor to NanoHive Medical.
“This capital infusion allows the company to capture the attention of leading surgeons and convert them to our best-in-class portfolio more aggressively. As we continue to produce consecutive month-over-month record sales, Kenston Capital’s participation enables this trend to continue,” said Patrick O’Donnell, CEO of NanoHive Medical.
NanoHive’s highly differentiated lattice structure provides enhanced visualization and reduced density as compared to alternatives, while also achieving sufficient durability and strength for biomechanical loads. Specifically designed geometry using a rhombic dodecahedron cell structure creates a base structure similar to cancellous bone, and provides ideal biomechanical elastic modulus properties. Manufactured with 3D printed titanium, the NanoHive interbody portfolio spans anterior and posterior lumbar, as well as cervical applications.
“We were drawn both to the value of the underlying IP and the exciting financial picture being painted from early, yet strong, commercial traction. Kenston Capital was delighted to participate in this debt financing, and looks forward to assisting other growth-stage life sciences and medical device companies,” commented James Kenney, Managing Partner of Kenston Capital Partners.
“At Outcome Capital, we pride ourselves in finding not only appropriate, but innovative capital solutions for our clients to take their companies and technologies to the next stage. It was a pleasure working with Kenston, and we are excited to see NanoHive take their next commercial step,” noted Arnold Freedman, Managing Partner of Outcome Capital.
About Outcome Capital, LLC
Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic, and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.
About Kenston Capital Partners, LLC
Kenston Capital Partners provides senior secured venture debt financing to high-growth, early-stage technology & healthcare companies. Through flexible and scalable transactions that leverage recent equity financings, Kenston Capital Partners provides minimally dilutive capital to enable our borrowers to execute on their growth and innovation trajectory. Since 2005, the Partners of Kenston Capital have originated more than $100 million in venture loans to more than 60 companies.